Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium

in Endocrine-Related Cancer

Type 2 diabetes (T2D) has been suggested to be a risk factor for multiple myeloma (MM), but the relationship between the two traits is still not well understood. The aims of this study were to evaluate whether 58 genome-wide-association-studies (GWAS)-identified common variants for T2D influence the risk of developing MM and to determine whether predictive models built with these variants might help to predict the disease risk. We conducted a case–control study including 1420 MM patients and 1858 controls ascertained through the International Multiple Myeloma (IMMEnSE) consortium. Subjects carrying the KCNQ1rs2237892T allele or the CDKN2A-2Brs2383208G/G, IGF1rs35767T/T and MADDrs7944584T/T genotypes had a significantly increased risk of MM (odds ratio (OR)=1.32–2.13) whereas those carrying the KCNJ11rs5215C, KCNJ11rs5219T and THADArs7578597C alleles or the FTOrs8050136A/A and LTArs1041981C/C genotypes showed a significantly decreased risk of developing the disease (OR=0.76–0.85). Interestingly, a prediction model including those T2D-related variants associated with the risk of MM showed a significantly improved discriminatory ability to predict the disease when compared to a model without genetic information (area under the curve (AUC)=0.645 vs AUC=0.629; P=4.05×1006). A gender-stratified analysis also revealed a significant gender effect modification for ADAM30rs2641348 and NOTCH2rs10923931 variants (Pinteraction=0.001 and 0.0004, respectively). Men carrying the ADAM30rs2641348C and NOTCH2rs10923931T alleles had a significantly decreased risk of MM whereas an opposite but not significant effect was observed in women (ORM=0.71 and ORM=0.66 vs ORW=1.22 and ORW=1.15, respectively). These results suggest that TD2-related variants may influence the risk of developing MM and their genotyping might help to improve MM risk prediction models.

Abstract

Type 2 diabetes (T2D) has been suggested to be a risk factor for multiple myeloma (MM), but the relationship between the two traits is still not well understood. The aims of this study were to evaluate whether 58 genome-wide-association-studies (GWAS)-identified common variants for T2D influence the risk of developing MM and to determine whether predictive models built with these variants might help to predict the disease risk. We conducted a case–control study including 1420 MM patients and 1858 controls ascertained through the International Multiple Myeloma (IMMEnSE) consortium. Subjects carrying the KCNQ1rs2237892T allele or the CDKN2A-2Brs2383208G/G, IGF1rs35767T/T and MADDrs7944584T/T genotypes had a significantly increased risk of MM (odds ratio (OR)=1.32–2.13) whereas those carrying the KCNJ11rs5215C, KCNJ11rs5219T and THADArs7578597C alleles or the FTOrs8050136A/A and LTArs1041981C/C genotypes showed a significantly decreased risk of developing the disease (OR=0.76–0.85). Interestingly, a prediction model including those T2D-related variants associated with the risk of MM showed a significantly improved discriminatory ability to predict the disease when compared to a model without genetic information (area under the curve (AUC)=0.645 vs AUC=0.629; P=4.05×1006). A gender-stratified analysis also revealed a significant gender effect modification for ADAM30rs2641348 and NOTCH2rs10923931 variants (Pinteraction=0.001 and 0.0004, respectively). Men carrying the ADAM30rs2641348C and NOTCH2rs10923931T alleles had a significantly decreased risk of MM whereas an opposite but not significant effect was observed in women (ORM=0.71 and ORM=0.66 vs ORW=1.22 and ORW=1.15, respectively). These results suggest that TD2-related variants may influence the risk of developing MM and their genotyping might help to improve MM risk prediction models.

Introduction

Multiple myeloma (MM) is a plasma-cell neoplasm of complex aetiology that may arise as a result of the interaction between adverse environmental and inherited genetic risk factors (Morgan et al. 2012). Although survival rates for MM have improved dramatically during the last two decades, likely due to the introduction of novel targeted therapies (proteasome inhibitors, immunomodulators and others), the disease outcome still remains poor with a 5-year overall survival rate not higher than 55% (Kumar et al. 2014).

Age, male gender, African ancestry and monoclonal gammopathy of uncertain significance (MGUS) have been established as major risk factors for MM (Alexander et al. 2007). In addition, exposure to a wide range of toxins as well as type 2 diabetes (T2D) and obesity have been suggested as important mediators of the complex process of myelomagenesis (Alexander et al. 2007, Lope et al. 2008, Wallin & Larsson 2011). Among these latter preventable factors, T2D has attracted significant attention since it has been consistently identified as a medical condition frequently found in MM patients (Khan et al. 2008, Richardson et al. 2009, Castillo et al. 2012) and it is thought to influence the myelomagenesis through hyperglycaemia and insulin-dependent and -independent mechanisms (Xu et al. 2014). In a recent well-powered meta-analysis, Castillo et al. (2012) observed that T2D was significantly associated with an increased risk of developing the disease (Castillo et al. 2012). This finding concurs with those previously reported in several epidemiological studies that showed a high incidence of T2D among MM patients ranging between 11 and 22% (Richardson et al. 2006, Badros et al. 2007). In addition, it has been reported that T2D may have a negative impact on MM prognosis (Chiu et al. 2006, Wu et al. 2014) and that the treatment with anti-diabetic drugs may effectively kill MM cells (Wu et al. 2014).

Considering that T2D and MM have strong genetic components and share several biological pathways and markers (Xu et al. 2014) and that T2D-related polymorphisms may influence the risk of developing solid cancer (Folsom et al. 2008, Cheng et al. 2011, Sainz et al. 2012, Ma et al. 2014), we hypothesized that genetic risk factors for T2D may be associated with the risk of developing MM. So far there have not been studies evaluating the impact of diabetogenic variants on the risk of developing hematological cancers. Therefore, we decided to conduct a multi-centre case–control study including 1420 MM patients and 1858 controls to evaluate whether 58 variants convincingly shown to be associated with T2D contribute to the risk of developing MM. We also aimed at determining whether predictive models including T2D-related variants significantly improve the discriminatory ability to predict the risk of MM.

Material and methods

Study population

The study population consisted of 1420 MM patients (705 women and 715 men) and 1858 controls (916 women and 942 men) ascertained through the International Multiple Myeloma (IMMEnSE) consortium (Supplementary Table 1, see section on supplementary data given at the end of this article), which has been described in detail elsewhere (Martino et al. 2012). The diagnosis of MM was assigned by physician and fulfilled the International Myeloma Working Group (IMWG) criteria (International Myeloma Working Group 2003). Controls were blood donors or hospitalized subjects with a diagnosis not related to cancer who were recruited in the same geographical area of the cases (Supplementary Table 1). Additional information concerning to the recruitment strategy of controls is shown in the Supplementary Material. The investigation was approved by the ethical committee of each participant institution, functioning according to the third edition of the Guidelines on the Practice of Ethical Committees in Medical Research issued by the Royal College of Physicians of London (www.rcplondon.ac.uk) and all participants gave their written informed consent to participate in the study.

SNP selection and genotyping

Fifty-eight genome-wide-association-studies (GWAS)-identified variants for T2D were selected to be genotyped in the IMMEnSE consortium population (Table 1 and Supplementary Material). The genotyping of the selected polymorphisms was carried out at GENYO (Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain) using KASPar assays (LGC Genomics, Hoddesdon, UK) according to manufacturer's instructions. For internal quality control, 5% of samples were randomly selected and included as duplicates. Concordance between the original and the duplicate samples for the 58 SNPs was ≥99.0%. Call rates for all SNPs were ≥90.0% with the exception of the WFS1rs734312 SNP that was excluded from further analyses.

Table 1

Selected type-2 diabetes-related SNPs

Gene namedbSNP rs#Nucleotide substitutionReference allele IMMEnSEGWAS-identified risk allele for T2DLocation/Aa substitutionReferences
ADAM30rs2641348T/CaTCL359PZeggini et al. (2008) and Lyssenko et al. (2009)
ADAMTS9rs4607103T/CCCNear geneMohlke et al. (2008), Zeggini et al. (2008) and Shu et al. (2010)
ADCY5rs11708067T/CTTIntronicDupuis et al. (2010) and Saxena et al. (2010)
ADRA2Ars10885122G/TGGNear ADRA2ADupuis et al. (2010)
ARAPI, CENTD2rs1552224G/TTANear geneVoight et al. (2010) and Nielsen et al. (2011)
BCL11Ars10490072C/TTTNear geneZeggini et al. (2008)
CDC123rs12779790A/GAGNear geneMohlke et al. (2008), Zeggini et al. (2008) and Shu et al. (2010)
CDKAL1rs7754840C/GGCIntronicDiabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research et al. (2007), Florez et al. (2007) and Scott et al. (2007)
CDKN2A-2Brs564398T/CTTNear geneDiabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research et al. (2007), Scott et al. (2007), Mohlke et al. (2008), Zeggini et al. (2008), Takeuchi et al. (2009), Shu et al. (2010) and Yamauchi et al. (2010)
CDKN2A-2Brs10811661T/CTTNear gene
CDKN2A-2Brs2383208A/GbAANear gene
COL5A1rs4240702C/TCNSIntronicBouatia-Naji et al. (2009)
CRY2rs11605924A/CCAIntronicDupuis et al. (2010)
DCDrs1153188A/TAANear geneZeggini et al. (2008)
EXT2rs1113132C/GCCIntronicFlorez et al. (2007) and Sladek et al. (2007)
FADS1rs174550C/TATIntronicDupuis et al. (2010)
FAM148Brs11071657A/GAANear geneChambers et al. (2008) and Dupuis et al. (2010)
FLJ39370rs17044137A/TTANear geneDiabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research et al. (2007)
FTOrs8050136A/CcCAIntronicWellcome Trust Case Control (2007), Zeggini et al. (2007) and Mohlke et al. (2008)
G6PC2rs560887G/AGGIntronicBouatia-Naji et al. (2008, 2009), Chen et al. (2008), Prokopenko et al. (2009) and Dupuis et al. (2010)
GCKrs1799884G/AGANear geneBouatia-Naji et al. (2008, 2009), Chen et al. (2008), Prokopenko et al. (2009) and Dupuis et al. (2010)
GCKRrs1260326C/TCTL445PBouatia-Naji et al. (2009), Dupuis et al. (2010) and Saxena et al. (2010)
HHEXrs1111875G/ACCNear geneDiabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research et al. (2007), Florez et al. (2007), Scott et al. (2007), Sladek et al. (2007), Wellcome Trust Case Control (2007), Zeggini et al. (2007) and Mohlke et al. (2008)
HMGA2rs1531343C/GGCNear geneVoight et al. (2010) and Nielsen et al. (2011)
HNF1A, TCF1rs7957197A/TTTIntronicVoight et al. (2010) and Nielsen et al. (2011)
IGF1rs35767C/TdCCNear genePechlivanis et al. (2007) and Dupuis et al. (2010)
IGF2BP2rs4402960G/TCTIntronicDiabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research et al. (2007), Florez et al. (2007), Scott et al. (2007), Wellcome Trust Case Control (2007), Zeggini et al. (2007), Mohlke et al. (2008) and Shu et al. (2010)
IL13rs20541C/TCTR144QDiabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research et al. (2007)
IRS1rs2943641C/TCCNear geneRung et al. (2009), Voight et al. (2010) and Tang et al. (2013)
JAZF1rs864745A/GATIntronicZeggini et al. (2008) and Shu et al. (2010)
KCNJ11rs5215T/CeTCV337IGloyn et al. (2003), Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research et al. (2007), Scott et al. (2007), Wellcome Trust Case Control (2007), Zeggini et al. (2007), Willer et al. (2007) and Mohlke et al. (2008)
KCNJ11rs5219C/TfCTK23E
KCNQ1rs2237897C/TTCIntronicUnoki et al. (2008), Yasuda et al. (2008), Tsai et al. (2010) and Yamauchi et al. (2010)
KCNQ1rs2074196G/TGGIntronic
KCNQ1rs2237892C/TgCCIntronic
KCNQ1rs2237895A/CACIntronic
KCNQ1OT1rs231362C/TCGIntronicTsai et al. (2010), Voight et al. (2010) and Nielsen et al. (2011)
LTArs1041981A/CeAAT60NHamid et al. (2005)
MADDrs7944584A/TdAAIntronicDupuis et al. (2010)
MCR4rs12970134A/GGANear geneChambers et al. (2008)
MTNR1Brs1387153C/TCTNear geneBouatia-Naji et al. (2009), Prokopenko et al. (2009) and Voight et al. (2010)
NOTCH2rs10923931G/ThGTIntronicMohlke et al. (2008) and Zeggini et al. (2008)
PKN2rs6698181C/TCTIntergenicDiabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research et al. (2007)
PPARGrs1801282C/GCCP12AAltshuler et al. (2000), Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research et al. (2007), Scott et al. (2007), Wellcome Trust Case Control (2007), Willer et al. (2007), Zeggini et al. (2007, 2008) and Mohlke et al. (2008)
PRC1rs8042680A/CCAIntronicVoight et al. (2010) and Nielsen et al. (2011)
PROX1rs340874A/GAGPromoterDupuis et al. (2010)
RBMS1rs7593730C/TCTIntronicQi et al. (2010)
SLC2A2rs11920090A/TATIntronicDupuis et al. (2010)
SLC30A8rs13266634C/TCCR325WDiabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research et al. (2007), Florez et al. (2007), Scott et al. (2007), Sladek et al. (2007), Steinthorsdottir et al. (2007), Wellcome Trust Case Control (2007), Zeggini et al. (2007), Mohlke et al. (2008), Dupuis et al. (2010) and Shu et al. (2010)
TCF2rs7501939C/TCCIntronicGudmundsson et al. (2007) and Sandhu et al. (2007)
TCF7L2rs7903146C/TCTIntronicGrant et al. (2006), Scott et al. (2006), Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research et al. (2007), Florez et al. (2007), Scott et al. (2007), Sladek et al. (2007), Steinthorsdottir et al. (2007), Wellcome Trust Case Control (2007), Zeggini et al. (2007), Mohlke et al. (2008), Dupuis et al. (2010) and Saxena et al. (2010)
TCF7L2rs12255372G/TGTIntronic
THADArs7578597T/CeTTT1187AZeggini et al. (2008)
TP53INP1rs896854A/GGGIntronicVoight et al. (2010) and Nielsen et al. (2011)
TSPAN8rs7961581C/TTCNear geneGrarup et al. (2008)
VEGFArs9472138C/TCTNear geneZeggini et al. (2008)
WFS1rs734312A/GANSH611RSandhu et al. (2007)
WFS1rs10010131A/GGGIntronicSandhu et al. (2007)

NS, not specified; Aa, aminoacid; GWAS, genome-wide association studies. Effect allele in bold and underlined.

C allele was associated with a decreased risk of MM in men whereas an opposite effect was detected in women.

G allele was associated with an increased risk of developing MM.

A/A genotype was associated with a decreased risk of MM (recessive model).

T/T genotype was associated with a decreased risk of MM (recessive model).

C allele was associated with a decreased risk of MM.

T allele was associated with an decreased risk of MM.

T allele was associated with an increased risk of MM.

T allele was associated with a decreased risk of MM in men whereas an opposite effect was detected in women.

Statistical analysis

The Hardy–Weinberg Equilibrium (HWE) tests were performed in the control group by a standard observed-expected χ2 test. Logistic regression analyses were used to assess the effects of the genetic polymorphisms on MM risk using co-dominant, dominant, recessive and log-additive inheritance models. Overall analyses were adjusted for age at diagnosis, gender and country of origin. All analyses were conducted using the statistical software SSPS (version 20.0). Statistical power was calculated using the Quanto vs12.4 (http://biostats.usc.edu/software) assuming a log-additive model.

In order to account for multiple testing, we calculated an adjusted significance level using the Meff method (Nyholt 2004), which considers the number of independent marker loci (MeffLi=55) but also the number of models of inheritance tested (co-dominant, dominant, recessive and log-additive). Thus, the resulting threshold for the main effect analysis was 0.00022 ((0.05/55)/4) (Supplementary Material). Since a study-wide significance threshold considering all these factors is generally perceived as a ‘too conservative’ test, we also assessed the magnitude of observed associations between selected SNPs and risk of MM through a quantile–quantile (QQ) plot generated from the results of the IMMEnSE population. The observed association P values were ranked in order from smallest to largest on the y-axis and plotted against the expected results from a theoretical ∼χ2-distribution under the null hypothesis of no association on the x-axis. A deviation from the identity line would confirm that the number of corresponding associations is more than expected under the null hypothesis and therefore that these associations are likely to be true associations.

Predictive models and discriminative accuracy

We also examined the value of T2D-related polymorphisms for prediction of MM using stepwise logistic and Cox regression analyses. We built a prediction model including age and sex and those genetic variants that showed significant associations with MM in the single-SNP analysis (P<0.05). Then, using P values as a selection criterion, we dropped variables that have the highest P value and we stopped when all variables were significant defined by P<0.10. The area under the curve (AUC) of a receiver operating characteristic (ROC) curve analysis was used to assess the discriminative accuracy of this particular model compared with a reference model including age and sex as covariates. A −2log likelihood ratio (LR) test was used to determine whether the predictive model including genetic information fitted significantly better the data compared to the reference model. Although the addition of genetic variables to the reference model will almost always make the model fit better, the LR test allowed us to confirm whether the difference in model fit between both models was statistically significant. Besides this suggestive analysis, we also ran a randomization test to confirm whether the improved predictive ability of the model including genetic variants significantly associated with MM was consistent after 10 000 iterations. We compared our full predictive model including significant SNPs, age and gender (‘original’ model) with 10 000 ‘randomized’ models in which the effect of SNPs on MM risk was neutralized by reassigning randomly all genotypes (null distribution; Supplementary Material). Subsequently, we calculated an empirical Piterations-value by dividing the number of times in which the ‘randomized’ AUC value was equal or greater than the ‘original’ AUC value by the number of iterations. Then, we could also calculate the Z score and PZ score-value for the original AUC using the ‘randomized’ AUC average of these 10 000 iterations and their s.d. All analyses were performed using R software (http://www.r-project.org/).

Gender-specific association analysis

We also evaluate gender-specific associations of selected SNPs with MM risk. Logistic regression analyses were corrected for age and country of origin. Of note, to evaluate whether a different gender distribution across populations within the IMMEnSE consortium could be responsible for the gender effect modification observed for certain SNPs, we also assessed heterogeneity and index I2 statistic using Cochran's χ2 based Q statistic test (Lau et al. 1997). Heterogeneity was considered significant when P<0.1.

Results

Overall associations of selected SNPs with MM risk

All SNPs were in HWE (P>0.001) with the exception of the COL5A1rs4240702, which was therefore excluded from the statistical analyses. Logistic regression analysis showed that carriers of the KCNQ1rs2237892T allele or the CDKN2A-2Brs2383208G/G, IGF1rs35767T/T and MADDrs7944584T/T genotypes had an increased risk of MM (odds ratio (OR)=1.32, 95% CI 1.01–1.71, P=0.039; OR=1.86, 95% CI 1.12–3.11, P=0.016; OR=2.13, 95% CI 1.35–3.37, P=0.0012 and OR=1.33, 95% CI 1.06–1.67, P=0.014, respectively) whereas those harbouring the KCNJ11rs5215C, KCNJ11rs5219T and THADArs7578597C alleles or the FTOrs8050136A/A and LTArs1041981C/C genotypes showed a decreased risk for the disease (OR=0.85, 95% CI 0.73–0.99, P=0.038; OR=0.84, 95% CI 0.72–0.99, P=0.034; OR=0.81, 95% CI 0.68–0.98, P=0.032; OR=0.78, 95% CI 0.64–0.95, P=0.013 and OR=0.76, 95% CI 0.58–0.99, P=0.042, respectively; Table 2). When we corrected for multiple testing (with a threshold of P=0.00022), none of the reported associations remained statistically significant. The strongest association observed was for the IGF1rs35767 SNP with an increased risk of developing MM (OR=2.13, 95% CI 1.35–3.37, P=0.0012). In spite of these results, the QQ plot showed an early deviation of identity line, which suggested a high proportion of true associations for a given P value (Fig. 1). Therefore, the data suggest that the effect attributed to SNPs in T2D-related loci (FTO, MADD, CDKN2A-2B, LTA) might represent true associations.

Table 2

Association of T2D-related variants and risk of developing MM

Variant_dbSNPGeneOverall (n=3278)Men (n=1657)Women (n=1621)Pinteraction
OR (95% CI)aP valueOR (95% CI)bP valueOR (95% CI)bP value
rs2641348cdADAM300.94 (0.78–1.14)0.530.71 (0.54–0.94)0.0151.22 (0.93–1.60)0.150.001
rs4607103ADAMTS91.00 (0.86–1.16)1.000.97 (0.79–1.20)0.801.05 (0.84–1.30)0.690.803
rs11708067ADCY51.02 (0.88–1.20)0.771.05 (0.85–1.31)0.640.97 (0.77–1.22)0.790.425
rs10885122ADRA2A1.08 (0.91–1.28)0.401.16 (0.92–1.47)0.210.99 (0.77–1.28)0.960.494
rs1552224eARAPI, CENTD21.16 (0.72–1.88)0.541.78 (0.96–3.29)0.0660.58 (0.25–1.37)0.200.090
rs10490072BCL11A1.01 (0.87–1.17)0.921.01 (0.82–1.25)0.911.01 (0.81–1.25)0.940.691
rs12779790CDC123, CAMK1D0.87 (0.74–1.02)0.0750.82 (0.66–1.03)0.0830.90 (0.71–1.13)0.350.758
rs7754840CDKAL10.98 (0.85–1.14)0.841.05 (0.86–1.29)0.630.91 (0.74–1.13)0.400.376
rs564398CDKN2A-2B0.94 (0.80–1.10)0.420.90 (0.72–1.11)0.330.97 (0.78–1.22)0.800.893
rs10811661CDKN2A-2B1.02 (0.87–1.20)0.791.11 (0.89–1.38)0.350.93 (0.74–1.17)0.520.358
rs2383208eCDKN2A-2B1.86 (1.12–3.11)0.0161.92 (1.03–3.58)0.0391.68 (0.69–4.10)0.250.585
rs11605924CRY20.93 (0.79–1.10)0.400.95 (0.75–1.19)0.640.92 (0.72–1.17)0.490.747
rs1153188DCD0.91 (0.79–1.06)0.240.83 (0.67–1.02)0.0821.05 (0.84–1.30)0.690.072
rs1113132eEXT20.92 (0.68–1.24)0.571.24 (0.83–1.87)0.300.64 (0.41–1.00)0.0460.067
rs174550FADS11.11 (0.95–1.28)0.181.13 (0.92–1.38)0.251.08 (0.87–1.34)0.480.359
rs11071657FAM148B1.03 (0.88–1.20)0.730.95 (0.77–1.17)0.621.16 (0.93–1.46)0.180.275
rs17044137FLJ393700.91 (0.78–1.05)0.191.05 (0.85–1.29)0.650.89 (0.72–1.11)0.300.357
rs8050136eFTO0.78 (0.64–0.95)0.0130.70 (0.53–0.93)0.0130.88 (0.66–1.17)0.370.420
rs560887eG6PC21.16 (0.88–1.52)0.300.98 (0.67–1.44)0.931.46 (0.98–2.18)0.0650.386
rs1799884cGCK1.10 (0.93–1.30)0.291.27 (1.01–1.61)0.0440.92 (0.72–1.18)0.510.254
rs1260326GCKR0.92 (0.78–1.08)0.320.93 (0.74–1.17)0.530.90 (0.71–1.13)0.360.926
rs1111875HHEX1.14 (0.98–1.33)0.0931.09 (0.88–1.36)0.411.21 (0.97–1.52)0.0950.452
rs35767eIGF12.13 (1.35–3.37)0.00121.69 (0.94–3.02)0.0793.13 (1.46–6.71)0.00260.538
rs4402960IGF2BP21.05 (0.91–1.22)0.520.95 (0.77–1.16)0.601.16 (0.93–1.44)0.180.304
rs20541IL131.01 (0.86–1.18)0.911.14 (0.92–1.42)0.220.88 (0.70–1.10)0.260.147
rs2943641IRS11.08 (0.93–1.26)0.311.16 (0.94–1.43)0.171.00 (0.80–1.24)0.990.492
rs864745eJAZF10.88 (0.74–1.04)0.140.98 (0.77–1.25)0.850.79 (0.61–1.01)0.0600.225
rs5215KCNJ110.85 (0.73–0.99)0.0380.89 (0.72–1.10)0.280.82 (0.66–1.02)0.0740.795
rs5219KCNJ110.84 (0.72–0.99)0.0340.92 (0.74–1.14)0.430.78 (0.62–0.98)0.0330.587
rs2237897cKCNQ11.25 (0.97–1.61)0.0811.08 (0.74–1.56)0.691.42 (1.00–2.01)0.0520.580
rs2074196KCNQ11.01 (0.75–1.37)0.930.80 (0.50–1.27)0.331.21 (0.81–1.81)0.350.456
rs2237892KCNQ11.32 (1.01–1.71)0.0391.15 (0.78–1.69)0.481.47 (1.03–2.10)0.0360.741
rs2237895KCNQ10.91 (0.77–1.08)0.280.94 (0.75–1.18)0.590.91 (0.71–1.16)0.440.878
rs231362KCNQ1OT11.03 (0.87–1.22)0.711.07 (0.85–1.34)0.591.01 (0.80–1.29)0.920.873
rs1041981eLTA0.76 (0.58–0.99)0.0420.85 (0.59–1.21)0.360.68 (0.45–1.01)0.0500.453
rs7944584eMADD1.33 (1.06–1.67)0.0141.47 (1.08–2.00)0.0151.16 (0.83–1.62)0.390.245
rs12970134MCR40.96 (0.82–1.11)0.581.01 (0.82–1.25)0.890.92 (0.72–1.18)0.510.643
rs1387153MTNR1B1.03 (0.89–1.19)0.731.01 (0.82–1.24)0.911.05 (0.85–1.30)0.670.761
rs10923931cNOTCH20.88 (0.73–1.06)0.160.66 (0.50–0.86)0.00191.15 (0.89–1.50)0.290.0004
rs7957197eHNF1A, OASL1.33 (0.93–1.92)0.121.60 (0.98–2.60)0.0591.04 (0.60–1.81)0.880.388
rs6698181PKN21.00 (0.85–1.17)0.991.10 (0.88–1.36)0.410.90 (0.72–1.12)0.340.450
rs1801282PPARG1.06 (0.89–1.26)0.521.02 (0.80–1.30)0.881.11 (0.86–1.43)0.430.655
rs8042680ePRC11.24 (0.99–1.55)0.0561.21 (0.89–1.64)0.241.37 (0.99–1.89)0.0550.777
rs340874PROX10.95 (0.80–1.13)0.550.90 (0.71–1.14)0.371.02 (0.79–1.30)0.890.387
rs7593730RBMS11.10 (0.95–1.29)0.201.18 (0.95–1.46)0.131.06 (0.85–1.33)0.580.852
rs1531343RPSAP52, HMGA20.96 (0.81–1.15)0.691.07 (0.84–1.37)0.570.86 (0.66–1.11)0.240.288
rs11920090SLC2A21.02 (0.86–1.20)0.841.17 (0.93–1.47)0.180.88 (0.68–1.12)0.290.257
rs13266634SLC30A80.91 (0.78–1.05)0.190.95 (0.78–1.17)0.640.86 (0.69–1.07)0.170.727
rs7501939TCF21.06 (0.91–1.24)0.431.06 (0.85–1.33)0.581.11 (0.89–1.38)0.370.440
rs7903146TCF7L20.99 (0.85–1.15)0.901.10 (0.89–1.36)0.370.88 (0.71–1.10)0.260.487
rs12255372TCF7L20.94 (0.81–1.09)0.431.06 (0.86–1.30)0.600.83 (0.67–1.03)0.0880.452
rs7578597cTHADA0.81 (0.68–0.98)0.0320.91 (0.70–1.18)0.470.73 (0.56–0.96)0.0250.125
rs896854cTP53INP11.17 (0.99–1.39)0.0721.22 (0.96–1.55)0.011.13 (0.88–1.45)0.330.269
rs7961581TSPAN8, LGR51.03 (0.89–1.19)0.711.03 (0.84–1.27)0.781.04 (0.84–1.29)0.710.973
rs9472138VEGFA1.13 (0.97–1.31)0.111.19 (0.97–1.46)0.101.09 (0.88–1.35)0.430.737
rs734312WFS10.98 (0.83–1.16)0.841.05 (0.83–1.33)0.670.90 (0.71–1.15)0.390.593
rs10010131WFS10.94 (0.80–1.10)0.421.11 (0.89–1.38)0.340.77 (0.62–0.96)0.0220.056

Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; NS, not specified. Estimates were adjusted for age, sex, country of origin. P<0.05 in bold.

Estimates calculated according to a dominant model of inheritance and adjusted for age, gender and region.

Estimates calculated according to a dominant model of inheritance and adjusted for age and region.

ADAM30rs2641348 (per-allele ORMEN=0.71, 95% CI 0.55–0.92; Ptrend=0.0072 vs per-allele ORWOMEN=1.29, 95% CI 1.00–1.65; Ptrend=0.046). GCKrs1799884 (per-allele ORMEN=1.24, 95% CI 1.00–1.54; Ptrend=0.050 vs per-allele ORWOMEN=0.94, 95% CI 0.75–1.18; Ptrend=0.58). KCNQ1rs2237897 (per-allele ORMEN=1.09, 95% CI 0.77–1.54; Ptrend=0.63 vs per-allele ORWOMEN=1.41, 95% CI 1.02–1.97; Ptrend=0.041). KCNQ1rs2237892 (per-allele ORMEN=1.13, 95% CI 0.77–1.66; Ptrend=0.52 vs per-allele ORWOMEN=1.47, 95% CI 1.04–2.08; Ptrend=0.030). NOTCH2rs10923931 (per-allele ORMEN=0.66, 95% CI 0.52–0.84; Ptrend=0.0007 vs per-allele ORWOMEN=1.22, 95% CI 0.96–1.56; Ptrend=0.010). THADArs7578597 (per-allele ORMEN=0.96, 95% CI 0.75–1.22; Ptrend=0.73 vs per-allele ORWOMEN=0.75, 95% CI 0.58–0.96; Ptrend=0.021). TP53INP1rs896854 (per-allele ORMEN=1.17, 95% CI 1.01–1.35; Ptrend=0.04 vs per-allele ORWOMEN=1.03, 95% CI 0.89–1.20; Ptrend=0.68).

ADAM30rs2641348 (ORRECESSIVE-MEN=0.36, 95% CI 0.12–1.13; P=0.060 vs ORRECESSIVE-WOMEN=4.40, 95% CI 1.44–13.40; P=0.0059).

Estimates calculated according to a recessive model of inheritance.

Figure 1

Download Figure

Figure 1

QQ plot used to evaluate the magnitude of observed associations of T2D-related variants with risk of MM. QQ plot was calculated assuming a recessive model of inheritance. Deviation from the expected distribution is observed above an expected X2 of 0.75. The x-axis is -log10 of the expected P values (under a null hypothesis of no effects) whereas the y-axis is -log10 values of the actual P values.

Citation: Endocrine-Related Cancer 22, 4; 10.1530/ERC-15-0029

Predictive value of T2D-related variants

In order to determine whether there was a joint effect of SNPs significantly associated with MM, we built a prediction model including gender and those nine SNPs showing overall significant associations with MM. After excluding the variables that did not remain significant in the model, the final model included six SNPs that increased the discriminatory ability to predict the risk of MM when compared with a reference model including age and gender as covariates (AUC=0.645 95% CI 0.624–0.666; Table 3). The LR test showed that the model including genetic variants fitted better the data than the reference model, and that the difference in model fit between both models was statistically significant (P=4.05×1006). In addition, when we evaluated whether the model including genetic variants was consistent in predicting better the MM risk, we found that it showed an AUC value systematically higher than those of the 10 000 randomized models (null distribution; Z score=6.42, P=6.81×1011; Supplementary Material), emphasizing the importance of considering genetic variants significantly associated with MM when building predictive models.

Table 3

Discriminative value AUC for models including T2D-related variants

SNPsP valueOR 95% CIAUC 95% CIab
Reference modelc
 Gender0.7310.972 (0.828–1.141)
 Age<2.00×10161.036 (1.030–1.042)0.629 (0.607–0.650)e
Predictive model built with six significant SNPsd
 IGF1rs357670.0042.076 (1.258–3.426)
 FTOrs80501360.0020.723 (0.586–0.892)
 MADDrs79445840.0941.218 (0.967–1.535)
 PRC1rs80426800.0611.261 (0.989–1.607)
 KCNJ11rs52150.0270.832 (0.706–0.980)
 KCNQ1rs22378920.0081.468 (1.106–1.950)
 Gender0.7761.024 (0.871–1.204)
 Age<2.00×10161.037 (1.031–1.043)0.645 (0.624–0.666)ef

Including age and gender as variables never dropped from models.

Compared with a baseline model with AUC=0.5.

Including age and gender as covariates.

SNPs showing a significant association with MM (P<0.05). After removing missing values, 2460 subjects were available for prediction capacity analysis.

A LR test showed that the model including genetic variants fitted the data better than the reference model and that the difference in model fit between both models was statistically significant (−2log likelihood ratio test, df=6, P=4.05×1006). residual deviance (reference model): 3380.4. residual deviance (significant SNPs model): 3345.2.

A sort analysis revealed that this model showed an AUC value systematically higher than those observed in 10 000 randomized models (null distribution; Z score=6.42, P=6.81×1011; Supplementary Material).

Gender-specific associations with MM risk

Interestingly, a gender-stratified analysis also revealed significant gender effect modifications for ADAM30rs2641348 and NOTCH2rs10923931 SNPs (Pinteraction =0.001 and 0.0004 respectively). For ADAM30rs2641348C and NOTCH2rs10923931T alleles, a significantly reduced risk for the disease was observed in men (per-allele OR=0.71, 95% CI 0.54–0.94, P=0.015 and per-allele OR=0.66, 95% CI 0.50–0.86, P=0.0019, respectively) whereas a non-significant opposite effect was seen in women (per-allele OR=1.22, 95% CI 0.93–1.60 and per-allele OR=1.15, 95% CI 0.89–1.50 respectively). A statistically significant heterogeneity, considering P<0.05 as a threshold, was also confirmed for these two SNPs (PHET=0.0039 and I2=87.99% and PHET=0.0024 and I2=89.12%, respectively), which supports the notion suggesting a role of gender in modulating the effect of these SNPs on MM risk. Although there was not a significant interaction with gender, we observed additional gender-specific associations for WFS1rs10010131, THADArs7578597, EXT2rs1113132 and GCKrs1799884 SNPs according to dominant or recessive models of inheritance (Table 2 and Supplementary Material).

When we took account of multiple testing (with a threshold of P=0.00022), we found that the effect of the IGF1rs35767 variant was stronger in women than men with an association approaching significance with an increased risk of developing MM (OR=3.13, 95% CI 1.46–6.71, P=0.0026 vs OR=1.69, 95% CI 0.94–3.02, P=0.079 respectively). In addition, we found that the association of NOTCH2rs10923931 SNP with a decreased risk of MM in men was close to significance according to dominant and log-additive models (OR=0.66, 95% CI 0.50–0.86, P=0.0019 and Ptrend=0.0007), which may suggest a gender-specific allele-dosage effect for this variant to modulate the disease risk (Pinteraction=0.0004; Table 2). According to a log-additive model, we also found that the association of the ADAM30rs2641348C allele with a decreased risk of MM in men showed a slight trend to be significant considering multiple testing (OR=0.71, 95% CI 0.55–0.92, P=0.0072) whereas, according to a recessive model, the association of the ADAM30rs2641348C/C genotype was also close to survive multiple testing correction (OR=4.40, 95% CI 1.44–13.40, P=0.00059; Table 2 and Supplementary Table 2, see section on supplementary data given at the end of this article).

Discussion

In the present study, we report for the first time evidence of significant associations between GWAS-identified T2D genetic variants and MM risk. We found that carriers of the KCNQ1rs2237892T allele, CDKN2A-2Brs2383208G/G, IGF1rs35767T/T and MADDrs7944584T/T genotypes were at increased risk of MM, whereas those carrying the KCNJ11rs5215C, KCNJ11rs5219T and THADArs7578597C alleles or the FTOrs8050136A/A and LTArs1041981C/C genotypes showed a decreased risk for the disease. The associations for the KCNQ1, CDKN2A-2B, IGF1, MADD, KCNJ11, and THADA gene variants with the risk of MM showed an opposite direction to those previously reported in the GWAS for T2D (i.e., the risk allele was the opposite for MM and T2DM), which points towards a non-diabetogenic mechanism underlying the effect of these variants to modulate the risk of the disease. In support of this hypothesis, several studies have suggested that, besides their influence on pancreatic function and insulin secretion through a wide variety of biological mechanisms, some of these genes may also act as tumour suppressor genes (Koh et al. 1995, Kim & Sharpless 2006, Than et al. 2013) and have an impact in the modulation of cell survival (Butt et al. 1999, Ortega et al. 2002, Sharifi et al. 2013), differentiation (Pancewicz et al. 2010), proliferation (Grimberg 2003, Pancewicz et al. 2010) and apoptosis (LeRoith et al. 1995, Li et al. 2008, Pancewicz et al. 2010). Interestingly, a recent study demonstrated that T2D status was not implicated in the relationship between HNF1B and JAZF1 variants and prostate cancer risk (Stevens et al. 2010), which is in line with our hypothesis suggesting that T2D-related variants may determine the risk of MM through non-diabetogenic mechanisms.

When we took into account multiple testing corrections, only the association of the IGF1rs35767 promoter polymorphism with an increased risk of developing MM remained close to significance (P=0.0012), which suggested that the IGF1 locus may play an important role in triggering cell proliferation in malignant plasma cells. In support of the hypothesis, it has been observed that IGF1 acts as a major growth factor in MM that, directly or in cooperation with other growth factors, induces MM cell growth and proliferation (Ferlin et al. 2000, Bommert et al. 2006, Sprynski et al. 2009) and can eventually lead to chemoresistance (Xu et al. 1997, Kuhn et al. 2012). Likewise, it has been also reported that treatment with metformin, an anti-diabetic drug that inhibits IGF1 signaling pathway, significantly reduces the risk of transformation from MGUS to symptomatic MM (American Society of Clinical Oncology Annual Meeting 2014; abstract 1532) and that constant use of this treatment may induce cell apoptosis (Rattan et al. 2012) and enhance the effectiveness of chemotherapeutic regimes in blood and solid cancers (Feng et al. 2011, Pan et al. 2012, Watson 2013). Interestingly, several authors have also reported that IGF1 and its analogues are associated with an increased death in patients with progressive MM (Standal et al. 2002, Chou et al. 2012, Wu et al. 2014), whereas the administration of metformin results in the reduction of deaths in patients with progressive disease (Wu et al. 2014).

In fact, Chen et al. (2013) recently demonstrated that the IGF1rs35767 SNP together with two neighbour SNPs constitutes a haplotype that efficiently regulates transcriptional activity (Chen et al. 2013). Similarly, several studies have consistently reported that carriers of the IGF1rs35767T allele showed significantly higher levels of circulating IGF1 than those harbouring the WT allele (Mannino et al. 2013, Sesti et al. 2014) and that the presence of this variant is associated with an increased risk of developing several types of cancer (Ollberding et al. 2012, Qian et al. 2014).

Although it is tempting to speculate that the IGF1rs35767 SNP may be responsible for the effect attributed to diabetes on the risk of MM, we believe that rather than acting separately to modulate the risk of the disease, this genetic variant acts along with additional variants within KCNQ1, CDKN2A-2B, MADD, KCNJ11, THADA, LTA and FTO genes to modulate the disease risk. In order to test this hypothesis, we decided to evaluate the predictive value of T2D-related polymorphisms for prediction of MM using stepwise logistic and Cox regression analyses. Interestingly, we found that adding genetic factors to a model without covariates (including only age and gender) substantially improved the prediction of disease development. A predictive model including six SNPs significantly associated with MM in the single analysis showed an adjusted concordance statistic AUC of 64.5% for MM. The consistency of this result was confirmed through a randomization test that showed that none of the 10 000 randomized models showed a higher AUC value than our ‘original’ model including six genetic variants, age and gender. The addition of genetic variants associated with MM at P<0.10 level did not improve the discriminatory ability to predict MM, which pointed towards a joint contribution of IGF1, FTO, MADD, PRC1, KCNJ11 and KCNQ1 polymorphisms to predict the risk of the disease. Although the prediction capacity of these models could be considered relatively small when compared with a reference model, the relative absence of current diagnostic factors for MM suggest that the use of genetic variants could be a good option to improve the prediction of the disease risk.

The association of the non-diabetogenic alleles or genotypes for the polymorphisms within KCNQ1, CDKN2A-2B, MADD, KCNJ11, THADA and FTO genes with the risk of MM suggests that these genes, rather than acting through an insulin-dependent mechanism, may modulate the risk of MM by acting as tumour suppressor genes (Duro et al. 1995) or through mechanisms promoting cancer cell apoptosis (Rippe et al. 2003, Turner et al. 2013). In support of this idea, it has been recently reported that most of these genes are highly expressed in tumours and that genetic polymorphisms in these loci are also associated with cancer development (Sauroja et al. 2000, Cander et al. 2014) and tumour progression (Chen et al. 2009).

The association of LTArs1041981 SNP with a decreased risk of MM showed a similar direction to that observed in the GWAS for T2D (LTArs1041981A as risk allele) suggests a diabetogenic effect of this SNP to modify the risk of MM. However, we could not dismiss the idea suggesting that observed association could be due to a different distribution of diabetics between MM cases and controls. Similarly, although the direction of the association for the FTOrs8050136 SNP with the risk of MM was opposite to the one observed in the GWAS for T2D, we could not rule out the possibility that the observed effect for this obesogenic SNP (Scuteri et al. 2007) could be due to significant differences in BMI between MM cases and controls. Further studies using well-characterized cohorts are needed to confirm these latter associations.

Although it was not the primary objective of this study, we also performed gender-stratified analysis to assess whether there was a gender effect modification of selected SNPs to modulate the risk of developing MM. Interestingly, we found a significant gender effect modification for ADAM30rs2641348, and NOTCH2rs10923931 SNPs, which suggested a gender-specific effect of these loci to modulate the risk of MM. We observed that, according to a log-additive model of inheritance, the association of the NOTCH2rs10923931 SNP with a decreased risk of MM in men and the association of ADAM30rs2641348C/C genotype with an increased risk of MM in women showed a marginal level of significance after correction for multiple testing. Recently, it has been demonstrated that NOTCH2 is highly expressed in MM cells and that it is a key regulator of MM pathogenesis (Colombo et al. 2013). In particular, it has been reported that the activation of the NOTCH2, which interacts with Wnt components, induces an exacerbated growth of MM cells and accelerated the course of the disease by promoting cancer stem cell self-renewal (Xu et al. 2012a) and resistance to chemotherapeutic agents (Xu et al. 2012b). Considering that NOTCH2rs10923931 and ADAM30rs2641348 are neighbour SNPs in strong linkage disequilibrium (Zeggini et al. 2008) and that they showed gender-specific associations with the risk of MM, we hypothesize that NOTCH2-ADAM30 might represent a gender-specific susceptibility region for MM. In support of this idea, it has been reported that gender-specific variants within NOTCH and WNT signalling pathways, which are involved in determining cell proliferation and differentiation, may lead to important gender-specific differences in tumour recurrence and chemoresistance (Paez et al. 2014).

Our study has both strengths and weaknesses. The major strength is the large sample size. To our knowledge, this is the first study to evaluate the overall and gender-specific associations of T2D-related variants with the risk of developing MM and to assess their predictive value for MM. Although the influence of diabetogenic variants on the risk of the disease was expected to be very modest, our study was sufficiently powered to detect such small effects. Based on the genotype frequencies observed in our study cohort, we had 80% of power (dominant model) to detect an OR of 1.29 at α=0.00022 (multiple testing threshold) for a polymorphism with a minor allele frequency of 0.25. Although the gender-stratified analysis reduced the statistical power to detect effect of SNPs, we still had 80% of power to detect ORs of 1.43 and 1.44 for men and women respectively. It is important to realise, however, that although the present study involves data on over 3334 individuals, the retrospective and multicentre study design places inevitable limitations on clinical data availability. T2D status and BMI were not available for a substantial subset of MM cases, which did not allow us to adjust our analyses for these variables and, consequently, to rule out the possibility that some of the reported associations could arise as a result of a different distribution of diabetics and/or obese subjects between MM cases and controls. Nonetheless, considering that most of the reported associations with MM risk showed a different direction to those previously published in the GWAS for T2D and given that most of these genes are not linked to obesity, we could not expect to find false positive associations due to these confounding factors.

In conclusion, our study indicate that T2D-related variants within IGF1, KCNJ11, CDKN2A-2B, MADD, THADA, LTA, FTO, ADAM30 and NOTCH2 genes may influence the risk of MM through insulin-independent mechanisms and that genotyping of specific T2D-related variants may be useful to improve the prediction of MM development. Additional work is needed to replicate our findings in independent and well-characterized populations and functional studies are also warranted to elucidate the biological mechanisms underlying the observed effects.

Supplementary data

This is linked to the online version of the paper at http://dx.doi.org/10.1530/ERC-15-0029.

Declaration of interest

V Andersen is receiving compensation as a consultant for MSD (Merck) and Janssen. The rest of the authors have nothing to disclose.

Funding

This work was supported by grants from the FIBAO foundation (Granada, Spain) and the CRIS foundation against cancer, from the Cancer Network of Excellence (RD12/10 Red de Cáncer) and from the Instituto de Salud Carlos III (Madrid, Spain; PI12/02688).

References

  • AlexanderDDMinkPJAdamiHOColePMandelJSOkenMMTrichopoulosD2007Multiple myeloma: a review of the epidemiologic literature. International Journal of Cancer120 (Suppl 12) 4061. (doi:10.1002/ijc.22718).

  • AltshulerDHirschhornJNKlannemarkMLindgrenCMVohlMCNemeshJLaneCRSchaffnerSFBolkSBrewerC2000The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genetics267680. (doi:10.1038/79839).

  • BadrosAGoloubevaODalalJSCanIThompsonJRapoportAPHeymanMAkpekGFentonRG2007Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer11010421049. (doi:10.1002/cncr.22921).

  • BommertKBargouRCStuhmerT2006Signalling and survival pathways in multiple myeloma. European Journal of Cancer4215741580. (doi:10.1016/j.ejca.2005.12.026).

  • Bouatia-NajiNRocheleauGVan LommelLLemaireKSchuitFCavalcanti-ProençaCMarchandMHartikainenALSovioUDe GraeveF2008A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science32010851088. (doi:10.1126/science.1156849).

  • Bouatia-NajiNBonnefondACavalcanti-ProençaCSparsøTHolmkvistJMarchandMDelplanqueJLobbensSRocheleauGDurandE2009A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nature Genetics418994. (doi:10.1038/ng.277).

  • ButtAJFirthSMBaxterRC1999The IGF axis and programmed cell death. Immunology and Cell Biology77256262. (doi:10.1046/j.1440-1711.1999.00822.x).

  • CanderSKarkucakMGulOOSagSOYakutTErsoyCTuncelEErturkE2014Association between p16(CDKN2A) C540G polymorphism and tumor behavior in prolactinoma: a single-center study. Biomedical Reports2589595. (doi:10.3892/br.2014.281).

  • CastilloJJMullNReaganJLNemrSMitriJ2012Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood11948454850. (doi:10.1182/blood-2011-06-362830).

  • ChambersJCElliottPZabanehDZhangWLiYFroguelPBaldingDScottJKoonerJS2008Common genetic variation near MC4R is associated with waist circumference and insulin resistance. Nature Genetics40716718. (doi:10.1038/ng.156).

  • ChenWMErdosMRJacksonAUSaxenaRSannaSSilverKDTimpsonNJHansenTOrrùMGrazia PirasM2008Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. Journal of Clinical Investigation11826202628. (doi:10.1172/JCI34566).

  • ChenJLiDKillaryAMSenSAmosCIEvansDBAbbruzzeseJLFrazierML2009Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Annals of Surgical Oncology16431439. (doi:10.1245/s10434-008-0220-8).

  • ChenHYHuangWLeungVHFungSLMaSLJiangHTangNL2013Functional interaction between SNPs and microsatellite in the transcriptional regulation of insulin-like growth factor 1. Human Mutation3412891297. (doi:10.1002/humu.22363).

  • ChengICabertoCPLum-JonesASeifriedAWilkensLRSchumacherFRMonroeKRLimUTiirikainenMKolonelLN2011Type 2 diabetes risk variants and colorectal cancer risk: the Multiethnic Cohort and PAGE studies. Gut6017031711. (doi:10.1136/gut.2011.237727).

  • ChiuBCGapsturSMGreenlandPWangRDyerA2006Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. 1523482354. (doi:10.1158/1055-9965.EPI-06-0007).

  • ChouYSYangCFChenHSYangSHYuYBHongYCLiuCYGauJPLiuJHChenPM2012Pre-existing diabetes mellitus in patients with multiple myeloma. European Journal of Haematology89320327. (doi:10.1111/j.1600-0609.2012.01828.x).

  • ColomboMMirandolaLPlatonovaNApicellaLBasileAFigueroaAJCobosEChiriva-InternatiMChiaramonteR2013Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes. Leukemia2710091018. (doi:10.1038/leu.2013.6).

  • SaxenaRVoightBFLyssenkoVBurttNPde BakkerPIChenHRoixJJKathiresanSHirschhornJN2007Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science31613311336. (doi:10.1126/science.1142358).

  • DupuisJLangenbergCProkopenkoISaxenaRSoranzoNJacksonAUWheelerEGlazerNLBouatia-NajiNGloynAL2010New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nature Genetics42105116. (doi:10.1038/ng.520).

  • DuroDBernardODella ValleVBergerRLarsenCJ1995A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene112129.

  • FengYHVelazquez-TorresGGullyCChenJLeeMHYeungSC2011The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. Journal of Cellular and Molecular Medicine15825836. (doi:10.1111/j.1582-4934.2010.01083.x).

  • FerlinMNorazNHertoghCBrochierJTaylorNKleinB2000Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. British Journal of Haematology111626634. (doi:10.1046/j.1365-2141.2000.02364.x).

  • FlorezJCManningAKDupuisJMcAteerJIrenzeKGianninyLMirelDBFoxCSCupplesLAMeigsJB2007A 100K genome-wide association scan for diabetes and related traits in the Framingham Heart Study: replication and integration with other genome-wide datasets. Diabetes5630633074. (doi:10.2337/db07-0451).

  • FolsomARPankowJSPeacockJMBielinskiSJHeissGBoerwinkleE2008Variation in TCF7L2 and increased risk of colon cancer: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care31905909. (doi:10.2337/dc07-2131).

  • GloynALWeedonMNOwenKRTurnerMJKnightBAHitmanGWalkerMLevyJCSampsonMHalfordS2003Large-scale association studies of variants in genes encoding the pancreatic β-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes52568572. (doi:10.2337/diabetes.52.2.568).

  • GrantSFThorleifssonGReynisdottirIBenediktssonRManolescuASainzJHelgasonAStefanssonHEmilssonVHelgadottirA2006Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nature Genetics38320323. (doi:10.1038/ng1732).

  • GrarupNAndersenGKrarupNTAlbrechtsenASchmitzOJørgensenTBorch-JohnsenKHansenTPedersenO2008Association testing of novel type 2 diabetes risk alleles in the JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9, and NOTCH2 loci with insulin release, insulin sensitivity, and obesity in a population-based sample of 4,516 glucose-tolerant middle-aged Danes. Diabetes5725342540. (doi:10.2337/db08-0436).

  • GrimbergA2003Mechanisms by which IGF-I may promote cancer. Cancer Biology & Therapy2630635. (doi:10.4161/cbt.2.6.678).

  • GudmundssonJSulemPSteinthorsdottirVBergthorssonJTThorleifssonGManolescuARafnarTGudbjartssonDAgnarssonBABakerA2007Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nature Genetics39977983. (doi:10.1038/ng2062).

  • HamidYHUrhammerSAGlümerCBorch-JohnsenKJørgensenTHansenTPedersenO2005The common T60N polymorphism of the lymphotoxin-α gene is associated with type 2 diabetes and other phenotypes of the metabolic syndrome. Diabetologia48445451. (doi:10.1007/s00125-004-1659-1).

  • International Myeloma Working GroupCriteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working GroupBritish Journal of Haematology1212003749757. (doi:10.1046/j.1365-2141.2003.04355.x).

  • KhanAEGalloVLinseisenJKaaksRRohrmannSRaaschou-NielsenOTjonnelandAJohnsenHEOvervadKBergmannMM2008Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition. Haematologica93842850. (doi:10.3324/haematol.12297).

  • KimWYSharplessNE2006The regulation of INK4/ARF in cancer and aging. Cell127265275. (doi:10.1016/j.cell.2006.10.003).

  • KohJEndersGHDynlachtBDHarlowE1995Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature375506510. (doi:10.1038/375506a0).

  • KuhnDJBerkovaZJonesRJWoessnerRBjorklundCCMaWDavisRELinPWangHMaddenTL2012Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood12032603270. (doi:10.1182/blood-2011-10-386789).

  • KumarSKDispenzieriALacyMQGertzMABuadiFKPandeySKapoorPDingliDHaymanSRLeungN2014Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia2811221128. (doi:10.1038/leu.2013.313).

  • LauJIoannidisJPSchmidCH1997Quantitative synthesis in systematic reviews. Annals of Internal Medicine127820826. (doi:10.7326/0003-4819-127-9-199711010-00008).

  • LeRoithDWernerHBeitner-JohnsonDRobertsCTJr1995Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Reviews16143163. (doi:10.1210/edrv-16-2-143).

  • LiHWangJMorGSklarJ2008A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. Science32113571361. (doi:10.1126/science.1156725).

  • LopeVPerez-GomezBAragonesNLopez-AbenteGGustavssonPPlatoNZockJPPollanM2008Occupation, exposure to chemicals, sensitizing agents, and risk of multiple myeloma in Sweden. 1731233127. (doi:10.1158/1055-9965.EPI-08-0343).

  • LyssenkoVNagornyCLErdosMRWierupNJonssonASpégelPBuglianiMSaxenaRFexMPulizziN2009Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nature Genetics418288. (doi:10.1038/ng.288).

  • MaRCSoWYTamCHLukAOHoJSWangYLamVKLeeHMKongAPTongPC2014Genetic variants for type 2 diabetes and new-onset cancer in Chinese with type 2 diabetes. Diabetes Research and Clinical Practice103328337. (doi:10.1016/j.diabres.2013.12.016).

  • ManninoGCGrecoADe LorenzoCAndreozziFMariniMAPerticoneFSestiG2013A fasting insulin-raising allele at IGF1 locus is associated with circulating levels of IGF-1 and insulin sensitivity. PLoS ONE8e85483. (doi:10.1371/journal.pone.0085483).

  • MartinoASainzJBudaGJamroziakKReisRMGarcia-SanzRJuradoMRiosRSzemraj-RoguckaZMarquesH2012Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). International Journal of Oncology40625638. (doi:10.3892/ijo.2011.1284).

  • MohlkeKLBoehnkeMAbecasisGR2008Metabolic and cardiovascular traits: an abundance of recently identified common genetic variants. Human Molecular Genetics17R102R108. (doi:10.1093/hmg/ddn275).

  • MorganGJWalkerBADaviesFE2012The genetic architecture of multiple myeloma. Nature Reviews. Cancer12335348. (doi:10.1038/nrc3257).

  • NielsenTSparsøTGrarupNJørgensenTPisingerCWitteDRDiabetes Genetics Replication and Meta-analysis (DIAGRAM) ConsortiumHansenTPedersenO2011Type 2 diabetes risk allele near CENTD2 is associated with decreased glucose-stimulated insulin release. Diabetologia5410521056. (doi:10.1007/s00125-011-2054-3).

  • NyholtDR2004A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. American Journal of Human Genetics74765769. (doi:10.1086/383251).

  • OllberdingNJChengIWilkensLRHendersonBEPollakMNKolonelLNLe MarchandL2012Genetic variants, prediagnostic circulating levels of insulin-like growth factors, insulin, and glucose and the risk of colorectal cancer: the Multiethnic Cohort study. 21810820. (doi:10.1158/1055-9965.EPI-11-1105).

  • OrtegaSMalumbresMBarbacidM2002Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochimica et Biophysica Acta16027387.

  • PaezDGergerAZhangWYangDLabonteMJBenhanimLKahnMLenzFLenzCNingY2014Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence. Pharmacogenomics Journal14142150. (doi:10.1038/tpj.2013.20).

  • PanJChenCJinYFuentes-MatteiEVelazquez-ToresGBenitoJMKonoplevaMAndreeffMLeeMHYeungSC2012Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle1123142326. (doi:10.4161/cc.20770).

  • PancewiczJTaylorJMDattaABaydounHHWaldmannTAHermineONicotC2010Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. PNAS1071661916624. (doi:10.1073/pnas.1010722107).

  • PechlivanisSWagnerKChang-ClaudeJHoffmeisterMBrennerHForstiA2007Polymorphisms in the insulin like growth factor 1 and IGF binding protein 3 genes and risk of colorectal cancer. Cancer Detection and Prevention31408416. (doi:10.1016/j.cdp.2007.10.001).

  • ProkopenkoILangenbergCFlorezJCSaxenaRSoranzoNThorleifssonGLoosRJManningAKJacksonAUAulchenkoY2009Variants in MTNR1B influence fasting glucose levels. Nature Genetics417781. (doi:10.1038/ng.290).

  • QiLCornelisMCKraftPStanyaKJLinda KaoWHPankowJSDupuisJFlorezJCFoxCSParéG2010Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes. Human Molecular Genetics1927062715. (doi:10.1093/hmg/ddq156).

  • QianJZhouHChenJDingQCaoQQinCShaoPLiPCaiHMengX2014Genetic polymorphisms in IGF-I and IGFBP-3 are associated with prostate cancer in the Chinese population. PLoS ONE9e85609. (doi:10.1371/journal.pone.0085609).

  • RattanRAli FehmiRMunkarahA2012Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. Journal of Oncology2012928127. (doi:10.1155/2012/928127).

  • RichardsonPGBriembergHJagannathSWenPYBarlogieBBerensonJSinghalSSiegelDSIrwinDSchusterM2006Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of Clinical Oncology2431133120. (doi:10.1200/JCO.2005.04.7779).

  • RichardsonPGSonneveldPSchusterMWStadtmauerEAFaconTHarousseauJLBen-YehudaDLonialSGoldschmidtHReeceD2009Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. British Journal of Haematology144895903. (doi:10.1111/j.1365-2141.2008.07573.x).

  • RippeVDrieschnerNMeiboomMMurua EscobarHBonkUBelgeGBullerdiekJ2003Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas. Oncogene2261116114. (doi:10.1038/sj.onc.1206867).

  • RungJCauchiSAlbrechtsenAShenLRocheleauGCavalcanti-ProençaCBacotFBalkauBBelisleABorch-JohnsenK2009Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nature Genetics4111101115. (doi:10.1038/ng.443).

  • SainzJRudolphAHoffmeisterMFrankBBrennerHChang-ClaudeJHemminkiKForstiA2012Effect of type 2 diabetes predisposing genetic variants on colorectal cancer risk. Journal of Clinical Endocrinology and Metabolism97E845E851. (doi:10.1210/jc.2011-2565).

  • SandhuMSWeedonMNFawcettKAWassonJDebenhamSLDalyALangoHFraylingTMNeumannRJShervaR2007Common variants in WFS1 confer risk of type 2 diabetes. Nature Genetics39951953. (doi:10.1038/ng2067).

  • SaurojaISmedsJVlaykovaTKumarRTalveLHahka-KemppinenMPunnonenKJansenCTHemminkiKPyrhonenS2000Analysis of G(1)/S checkpoint regulators in metastatic melanoma. 28404414. (doi:10.1002/1098-2264(200008)28:4<404::AID-GCC6>3.0.CO;2-P).

  • SaxenaRHivertMFLangenbergCTanakaTPankowJSVollenweiderPLyssenkoVBouatia-NajiNDupuisJJacksonAU2010Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nature Genetics42142148. (doi:10.1038/ng.521).

  • ScottLJBonnycastleLLWillerCJSprauAGJacksonAUNarisuNDurenWLChinesPSStringhamHMErdosMR2006Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes5526492653. (doi:10.2337/db06-0341).

  • ScottLJMohlkeKLBonnycastleLLWillerCJLiYDurenWLErdosMRStringhamHMChinesPSJacksonAU2007A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science31613411345. (doi:10.1126/science.1142382).

  • ScuteriASannaSChenWMUdaMAlbaiGStraitJNajjarSNagarajaROrruMUsalaG2007Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genetics3e115. (doi:10.1371/journal.pgen.0030115).

  • SestiGManninoGCAndreozziFGrecoAPerticoneMSciacquaAMariniMAPerticoneF2014A polymorphism at IGF1 locus is associated with carotid intima media thickness and endothelium-dependent vasodilatation. Atherosclerosis2322530. (doi:10.1016/j.atherosclerosis.2013.10.024).

  • SharifiSDaghighiSMotazackerMMBadlouBSanjabiBAkbarkhanzadehARowshaniATLaurentSPeppelenboschMPRezaeeF2013Superparamagnetic iron oxide nanoparticles alter expression of obesity and T2D-associated risk genes in human adipocytes. Scientific Reports32173. (doi:10.1038/srep02173).

  • ShuXOLongJCaiQQiLXiangYBChoYSTaiESLiXLinXChowWH2010Identification of new genetic risk variants for type 2 diabetes. PLoS Genetics6e1001127. (doi:10.1371/journal.pgen.1001127).

  • SladekRRocheleauGRungJDinaCShenLSerreDBoutinPVincentDBelisleAHadjadjS2007A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature445881885. (doi:10.1038/nature05616).

  • SprynskiACHoseDCaillotLRemeTShaughnessyJDJrBarlogieBSeckingerAMoreauxJHundemerMJourdanM2009The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood11346144626. (doi:10.1182/blood-2008-07-170464).

  • StandalTBorsetMLenhoffSWisloffFStordalBSundanAWaageASeidelC2002Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood10039253929. (doi:10.1182/blood-2002-05-1406).

  • SteinthorsdottirVThorleifssonGReynisdottirIBenediktssonRJonsdottirTWaltersGBStyrkarsdottirUGretarsdottirSEmilssonVGhoshS2007A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nature Genetics39770775. (doi:10.1038/ng2043).

  • StevensVLAhnJSunJJacobsEJMooreSCPatelAVBerndtSIAlbanesDHayesRB2010HNF1B and JAZF1 genes, diabetes, and prostate cancer risk. Prostate70601607. (doi:10.1002/pros.21094).

  • TakeuchiFSerizawaMYamamotoKFujisawaTNakashimaEOhnakaKIkegamiHSugiyamaTKatsuyaTMiyagishiM2009Confirmation of multiple risk Loci and genetic impacts by a genome-wide association study of type 2 diabetes in the Japanese population. Diabetes5816901699. (doi:10.2337/db08-1494).

  • TangYHanXSunXLvCZhangXGuoWRenQLuoYZhangXZhouX2013Association study of a common variant near IRS1 with type 2 diabetes mellitus in Chinese Han population. Endocrine438491. (doi:10.1007/s12020-012-9693-0).

  • ThanBLGoosJASarverALO'SullivanMGRodAStarrTKFijnemanRJMeijerGAZhaoLZhangY2013The role of KCNQ1 in mouse and human gastrointestinal cancers. Oncogene3338613868. (doi:10.1038/onc.2013.350).

  • TsaiFJYangCFChenCCChuangLMLuCHChangCTWangTYChenRHShiuCFLiuYM2010A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese. PLoS Genetics6e1000847. (doi:10.1371/journal.pgen.1000847).

  • TurnerALiLCPilliTQianLWileyELSettySChristovKGaneshLMakerAVLiP2013MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. PLoS ONE8e56817. (doi:10.1371/journal.pone.0056817).

  • UnokiHTakahashiAKawaguchiTHaraKHorikoshiMAndersenGNgDPHolmkvistJBorch-JohnsenKJørgensenT2008SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nature Genetics4010981102. (doi:10.1038/ng.208).

  • VoightBFScottLJSteinthorsdottirVMorrisAPDinaCWelchRPZegginiEHuthCAulchenkoYSThorleifssonG2010Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nature Genetics42579589. (doi:10.1038/ng.609).

  • WallinALarssonSC2011Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. European Journal of Cancer4716061615. (doi:10.1016/j.ejca.2011.01.020).

  • WatsonJ2013Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biology3120144. (doi:10.1098/rsob.120144).

  • Wellcome Trust Case ControlC2007Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature447661678. (doi:10.1038/nature05911).

  • WillerCJBonnycastleLLConneelyKNDurenWLJacksonAUScottLJNarisuNChinesPSSkolAStringhamHM2007Screening of 134 single nucleotide polymorphisms (SNPs) previously associated with type 2 diabetes replicates association with 12 SNPs in nine genes. Diabetes56256264. (doi:10.2337/db06-0461).

  • WuWMerrimanKNabaahASevalNSevalDLinHWangMQazilbashMHBaladandayuthapaniVBerryD2014The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. British Journal of Cancer111628636. (doi:10.1038/bjc.2014.307).

  • XuFGardnerATuYMichlPPragerDLichtensteinA1997Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. British Journal of Haematology97429440. (doi:10.1046/j.1365-2141.1997.592708.x).

  • XuDHuJXuSDe BruyneEMenuEVan CampBVanderkerkenKVan ValckenborghE2012aDll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation. Leukemia2614021405. (doi:10.1038/leu.2011.332).

  • XuDHuJDe BruyneEMenuESchotsRVanderkerkenKVan ValckenborghE2012bDll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma. Biochemical and Biophysical Research Communications428518524. (doi:10.1016/j.bbrc.2012.10.071).

  • XuCXZhuHHZhuYM2014Diabetes and cancer: associations, mechanisms, and implications for medical practice. World Journal of Diabetes5372380. (doi:10.4239/wjd.v5.i3.372).

  • YamauchiTHaraKMaedaSYasudaKTakahashiAHorikoshiMNakamuraMFujitaHGrarupNCauchiS2010A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nature Genetics42864868. (doi:10.1038/ng.660).

  • YasudaKMiyakeKHorikawaYHaraKOsawaHFurutaHHirotaYMoriHJonssonASatoY2008Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nature Genetics4010921097. (doi:10.1038/ng.207).

  • ZegginiEWeedonMNLindgrenCMFraylingTMElliottKSLangoHTimpsonNJPerryJRRaynerNWFreathyRM2007Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science31613361341. (doi:10.1126/science.1142364).

  • ZegginiEScottLJSaxenaRVoightBFMarchiniJLHuTde BakkerPIAbecasisGRAlmgrenPAndersenG2008Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nature Genetics40638645. (doi:10.1038/ng.120).

(R Ríos and C B Lupiañez contributed equally to this work)

 

An official journal of

Society for Endocrinology

Sections

Figures

  • View in gallery

    QQ plot used to evaluate the magnitude of observed associations of T2D-related variants with risk of MM. QQ plot was calculated assuming a recessive model of inheritance. Deviation from the expected distribution is observed above an expected X2 of 0.75. The x-axis is -log10 of the expected P values (under a null hypothesis of no effects) whereas the y-axis is -log10 values of the actual P values.

Index Card

PubMed

Google Scholar

Related Articles

Altmetrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 339 339 123
PDF Downloads 38 38 22